A multi-center randomized, double blinded phase IIb trial evaluating oral pooled fecal microbiotherapy MaaT033 to prevent allogeneic hematopoietic cell transplantation complications

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2022-501831-18-00

Acronym

MPOH08

Enrollment

374

Registered

2023-03-03

Start date

2023-09-13

Completion date

Unknown

Last updated

2026-01-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Patients with hematologic malignancies and undergoing allogenic hematopoietic cell transplantation

Brief summary

Parameter: Overall survival (OS). For this endpoint, OS is defined as the time from the date of alloHCT to the date of death from any cause.

Detailed description

See table 1 of the protocol for details

Interventions

DRUGMaaT033

DRUGPlacebo is an inert coated capsule with no microbiota (active substance) inside. It is composed of a mix of coloring agents and partially pre-gelatinized corn starch in Hydroxypropyl methylcellulose capsule.

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Parameter: Overall survival (OS). For this endpoint, OS is defined as the time from the date of alloHCT to the date of death from any cause.	—

Secondary

Measure	Time frame
See table 1 of the protocol for details	—

Countries

Belgium, France, Germany, Netherlands, Spain

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026